A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment

被引:40
作者
Durez, P
Toukap, AN
Lauwerys, BR
Manicourt, DH
Verschueren, P
Westhovens, R
Devogelaer, JP
Houssiau, FA
机构
[1] Catholic Univ Louvain, Clin Univ St Luc, Dept Rheumatol, B-1200 Brussels, Belgium
[2] Katholieke Univ Leuven, UZ Gasthuisberg, Dept Rheumatol, Louvain, Belgium
关键词
D O I
10.1136/ard.2003.012914
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To compare the short term clinical and biological effects of intravenous (IV) pulse methylprednisolone (MP) and infliximab (IFX) in patients with severe active rheumatoid arthritis (RA) despite methotrexate (MTX) treatment. Methods: Patients with active RA despite MTX treatment were randomly allocated to receive a single IV infusion of MP (1 g) or three IV infusions of IFX (3 mg/kg) on weeks 0, 2, and 6. Patients were "blindly'' evaluated for disease activity measures. Quality of life (QoL) was evaluated through the SF-36 health survey. Serum matrix metalloproteinase-3 (MMP-3) titres were measured at baseline, weeks 2 and 6. Results: Compared with baseline, significant improvement was noted in all activity measures, including serum C reactive protein (CRP) titres, in the IFX group only. At week 14, 6/9 (67%) and 4/9 (44%) IFX patients met the ACR20 and 50 response criteria, while this was the case in only 1/12 (8%) and 0/12 (0%) MP patients, respectively (p<0.05). None of the QoL scales improved with MP treatment, whereas some did so in the IFX group. Serum MMP-3 titres significantly decreased (41% drop) at week 6 in the IFX group, while no changes were seen in patients given MP. Conclusion: This short term randomised comparative study demonstrates that TNF blockade is better than MP pulse therapy in a subset of patients with severe refractory RA, with improvement in not only clinical parameters of disease activity but also biological inflammatory indices, such as serum CRP and MMP-3 titres.
引用
收藏
页码:1069 / 1074
页数:6
相关论文
共 25 条
  • [1] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS
    ARNETT, FC
    EDWORTHY, SM
    BLOCH, DA
    MCSHANE, DJ
    FRIES, JF
    COOPER, NS
    HEALEY, LA
    KAPLAN, SR
    LIANG, MH
    LUTHRA, HS
    MEDSGER, TA
    MITCHELL, DM
    NEUSTADT, DH
    PINALS, RS
    SCHALLER, JG
    SHARP, JT
    WILDER, RL
    HUNDER, GG
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (03): : 315 - 324
  • [2] Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
    Boers, M
    Verhoeven, AC
    Markusse, HM
    vandeLaar, MAFJ
    Westhovens, R
    vanDenderen, JC
    vanZeben, D
    Dijkmans, BAC
    Peeters, AJ
    Jacobs, P
    vandenBrink, HR
    Schouten, HJA
    vanderHeijde, DMFM
    Boonen, A
    vanderLinden, S
    [J]. LANCET, 1997, 350 (9074) : 309 - 318
  • [3] Brennan FM, 1997, BRIT J RHEUMATOL, V36, P643
  • [4] Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens:: current questions and tentative answers in rheumatology
    Buttgereit, F
    da Silva, JAP
    Boers, M
    Burmester, GR
    Cutolo, M
    Jacobs, J
    Kirwan, J
    Köhler, L
    van Riel, P
    Vischer, T
    Bijlsma, JWJ
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (08) : 718 - 722
  • [5] Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases
    Cawson, T
    [J]. MOLECULAR MEDICINE TODAY, 1998, 4 (03): : 130 - 137
  • [6] Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial
    Choy, EHS
    Isenberg, DA
    Garrood, T
    Farrow, S
    Ioannou, Y
    Bird, H
    Cheung, N
    Williams, B
    Hazleman, B
    Price, R
    Yoshizaki, K
    Nishimoto, N
    Kishimoto, T
    Panayi, GS
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (12): : 3143 - 3150
  • [7] PULSE TREATMENT WITH METHYLPREDNISOLONE IN RHEUMATOID-ARTHRITIS
    CORKILL, MM
    GIBSON, T
    PANAYI, GS
    [J]. BRITISH MEDICAL JOURNAL, 1990, 301 (6749) : 446 - 446
  • [8] INTERLEUKIN-6 IN SYNOVIAL-FLUID AND SERUM OF PATIENTS WITH RHEUMATOID-ARTHRITIS AND OTHER INFLAMMATORY ARTHRITIDES
    HOUSSIAU, FA
    DEVOGELAER, JP
    VANDAMME, J
    DEDEUXCHAISNES, CN
    VANSNICK, J
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (06): : 784 - 788
  • [9] Infliximab and methotrexate in the treatment of rheumatoid arthritis
    Lipsky, PE
    van der Heijde, DMFM
    St Clair, EW
    Furst, DE
    Breedveld, FC
    Kalden, JR
    Smolen, JS
    Weisman, M
    Emery, P
    Feldmann, M
    Harriman, GR
    Maini, RN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) : 1594 - 1602
  • [10] Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial
    Maini, R
    St Clair, EW
    Breedveld, F
    Furst, D
    Kalden, J
    Weisman, M
    Smolen, J
    Emery, P
    Harriman, G
    Feldmann, M
    Lipsky, P
    [J]. LANCET, 1999, 354 (9194) : 1932 - 1939